Affiliation:
1. Discovery Chemistry Research, Arromax Pharmatech Co. Ltd. Sangtian Island Science & Technology Innovation Park, No. 1 Huayun Road, SIP, Suzhou 215123, China
Abstract
Breast cancer, the most common health burden to women globally, is considered a major
cause of death for women every year. Many signal transduction pathways can cause breast cancer.
The kinase inhibitors can interrupt the signaling pathways, minimize tumor growth and consequently
cure the disease. The scientists have discovered many kinase inhibitors as targeted drugs for breast
cancer. In recent years, the inhibitors of EGFR, HER2, VEGFR, PI3K, CDK4/6, PARP and hormone
receptor have been studied well for curing breast cancer. The FDA has approved a few kinase drugs
such as trastuzumab, lapatinib, neratinib, palbociclib, abemaciclib, alpelisib to treat breast cancer recently.
In this review, we summarized the latest development of kinase inhibitors as breast cancer
therapy.
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,Molecular Medicine,Biochemistry
Reference111 articles.
1. DeSantis C.E.; Ma J.; Gaudet M.M.; Newman L.A.; Miller K.D.; Goding Sauer A.; Jemal A.; Siegel R.L.; Breast cancer statistics, 2019. CA Cancer J Clin 2019,69(6),438-451
2. Dai X.; Li T.; Bai Z.; Yang Y.; Liu X.; Zhan J.; Shi B.; Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res 2015,5(10),2929-2943
3. Dawood S.; Triple-negative breast cancer: epidemiology and management options. Drugs 2010,70(17),2247-2258
4. Tamimi R.M.; Colditz G.A.; Hazra A.; Baer H.J.; Hankinson S.E.; Rosner B.; Marotti J.; Connolly J.L.; Schnitt S.J.; Collins L.C.; Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. Breast Cancer Res Treat 2012,131(1),159-167
5. Lin N.U.; Winer E.P.; Brain metastases: the HER2 paradigm. Clin Cancer Res 2007,13(6),1648-1655
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献